BTIG Downgrades Theravance Biopharma to Neutral
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
BTIG downgraded Theravance Biopharma (TBPH) to Neutral from Buy after Zymeworks (ZYME) announced it has agreed to acquire the company for $17 per share. The firm does not anticipate any materially higher offers and expects the deal to close in the second half, the analyst tells investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TBPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TBPH
Wall Street analysts forecast TBPH stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 17.000
Low
13.00
Averages
28.40
High
42.00
Current: 17.000
Low
13.00
Averages
28.40
High
42.00
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jones Trading Downgrades Theravance to Hold Amid $929M Acquisition
- Rating Downgrade: Jones Trading has downgraded Theravance Biopharma from buy to hold, reflecting a cautious outlook on its future performance, particularly in light of Zymeworks' acquisition for $929 million.
- Acquisition Details: Zymeworks is acquiring Theravance at $17 per share, representing a 22% premium over the closing price on March 3, and the transaction is not expected to raise antitrust concerns, indicating a favorable market reception.
- Clinical Results Impact: The positive phase 3 results for ampreloxetine, reported on March 3, initially boosted market sentiment, but the downgrade suggests analysts are wary of the company's trajectory following the acquisition announcement.
- Investor Movements: Summers Value Fund increased its stake in TBPH while exiting ADMA in Q1, indicating that investors still see potential value in Theravance despite the downgrade, reflecting mixed sentiments in the market.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as Iridium Communications Inc., Theravance Biopharma, Inc., Synaptics Incorporated, and Bio-Techne Corporation for potential violations of federal securities laws and breaches of fiduciary duties, which may affect shareholder rights.
- Transaction Details: Iridium Communications Inc. is set to be sold for $27.00 per share in cash and Rocket Lab stock, while Theravance Biopharma, Inc. is priced at $17.00 per share, Synaptics Incorporated at 1.350 shares of onsemi stock per share, and Bio-Techne Corporation at $73.00 per share in cash.
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact the firm to discuss their rights and options at no cost, aiming to provide legal support and potential compensation for affected investors.
- Legal Service Commitment: The law firm commits to handling cases on a contingent fee basis, meaning shareholders will not be responsible for upfront legal fees or expenses, ensuring that more investors can access legal assistance.
See More
Investigation into Theravance Biopharma's Transaction with Zymeworks
- Shareholder Compensation: Theravance Biopharma shareholders will receive $17.00 per share in cash, amounting to an equity value of approximately $929 million, along with a contingent value right entitling them to 80% of net proceeds from future monetization of ampreloxetine over the next decade, highlighting the company's commitment to shareholder value.
- Board Responsibility Investigation: Ademi LLP is investigating whether the Theravance Biopharma board has breached its fiduciary duties, particularly in the context of the transaction with Zymeworks, raising concerns about the board's consideration of all shareholders' interests and the transparency of corporate governance.
- Competing Transaction Restrictions: The transaction agreement imposes significant penalties on Theravance Biopharma for accepting competing bids, which could undermine potential shareholder benefits and reflects risks in the company's strategic decision-making process.
- Internal Conflicts of Interest: Insiders at Theravance Biopharma will receive substantial benefits as part of change of control arrangements, raising concerns about governance and conflicts of interest, which may affect investor confidence in the company's future prospects.
See More
Theravance Biopharma Acquired by Zymeworks for $17.00 per Share
- Deal Overview: Zymeworks is acquiring Theravance Biopharma for $17.00 per share in cash, totaling an equity value of $929 million, which represents a 22% premium over the stock's closing price on March 3, 2026, indicating recognition of Theravance's future potential.
- Future Earnings Rights: Theravance shareholders will receive a contingent value right entitling them to 80% of net proceeds related to ampreloxetine over the next ten years, providing additional revenue opportunities for shareholders while enhancing Zymeworks' strategic value.
- Clinical Trial Impact: The topline results of Theravance's CYPRESS phase 3 study, announced on March 3, did not meet its primary endpoint, leading to the decision to wrap up the ampreloxetine program, which may affect the company's future R&D direction and market performance.
- Market Reaction: Following the acquisition announcement, Theravance's stock was down over 2.5% in premarket trading, reflecting cautious market sentiment towards the deal and indicating investor uncertainty regarding the company's future prospects.
See More
Zymeworks Acquires Theravance Biopharma for $929M
- Acquisition Overview: Zymeworks announced its acquisition of Theravance Biopharma in an all-cash deal valued at approximately $929 million, paying $17 per share, aimed at expanding its commercial portfolio with the COPD treatment YUPELRI.
- Financial Impact Analysis: YUPELRI currently generates about $60 million in annual cash flow, and the acquisition includes additional royalty interests, milestone payments, and approximately $2.5 billion in Irish tax attributes, which are expected to significantly enhance Zymeworks' financial position.
- Financing Structure: The deal will be financed primarily through a $350 million non-recourse note from OMERS Life Sciences, Theravance's expected $360 million net cash balance at closing, and $219 million of Zymeworks' cash, showcasing a diverse financing strategy.
- Approval and Expectations: The boards of both companies have unanimously approved the transaction, which is expected to close in the second half of 2026; however, TBPH stock dropped 3% in pre-market trading on Monday, indicating some market skepticism despite the deal's long-term strategic significance.
See More
Theravance Biopharma Acquired by Zymeworks for $17 per Share
- Acquisition Agreement: Theravance Biopharma has entered into a definitive agreement with Zymeworks to be acquired for $17 per share in cash, representing an equity value of approximately $929 million, reflecting market recognition of Theravance's assets.
- Shareholder Benefit Assurance: In addition to cash, Theravance shareholders will receive a contingent value right entitling them to 80% of net proceeds from any future licensing or monetization of ampreloxetine over the next ten years, ensuring their interests in potential future gains.
- Strategic Review Outcome: This transaction is the result of a comprehensive evaluation by Theravance's Strategic Review Committee aimed at maximizing shareholder value, which previously included monetizing the TRELEGY® royalty for $225 million.
- Future Outlook: The transaction is expected to close in the second half of 2026, subject to shareholder and regulatory approvals, providing immediate cash flow to Theravance shareholders while preserving opportunities for future potential earnings.
See More
Jones Trading Downgrades Theravance to Hold Amid $929M Acquisition
- Rating Downgrade: Jones Trading has downgraded Theravance Biopharma from buy to hold, reflecting a cautious outlook on its future performance, particularly in light of Zymeworks' acquisition for $929 million.
- Acquisition Details: Zymeworks is acquiring Theravance at $17 per share, representing a 22% premium over the closing price on March 3, and the transaction is not expected to raise antitrust concerns, indicating a favorable market reception.
- Clinical Results Impact: The positive phase 3 results for ampreloxetine, reported on March 3, initially boosted market sentiment, but the downgrade suggests analysts are wary of the company's trajectory following the acquisition announcement.
- Investor Movements: Summers Value Fund increased its stake in TBPH while exiting ADMA in Q1, indicating that investors still see potential value in Theravance despite the downgrade, reflecting mixed sentiments in the market.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as Iridium Communications Inc., Theravance Biopharma, Inc., Synaptics Incorporated, and Bio-Techne Corporation for potential violations of federal securities laws and breaches of fiduciary duties, which may affect shareholder rights.
- Transaction Details: Iridium Communications Inc. is set to be sold for $27.00 per share in cash and Rocket Lab stock, while Theravance Biopharma, Inc. is priced at $17.00 per share, Synaptics Incorporated at 1.350 shares of onsemi stock per share, and Bio-Techne Corporation at $73.00 per share in cash.
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact the firm to discuss their rights and options at no cost, aiming to provide legal support and potential compensation for affected investors.
- Legal Service Commitment: The law firm commits to handling cases on a contingent fee basis, meaning shareholders will not be responsible for upfront legal fees or expenses, ensuring that more investors can access legal assistance.
See More
Investigation into Theravance Biopharma's Transaction with Zymeworks
- Shareholder Compensation: Theravance Biopharma shareholders will receive $17.00 per share in cash, amounting to an equity value of approximately $929 million, along with a contingent value right entitling them to 80% of net proceeds from future monetization of ampreloxetine over the next decade, highlighting the company's commitment to shareholder value.
- Board Responsibility Investigation: Ademi LLP is investigating whether the Theravance Biopharma board has breached its fiduciary duties, particularly in the context of the transaction with Zymeworks, raising concerns about the board's consideration of all shareholders' interests and the transparency of corporate governance.
- Competing Transaction Restrictions: The transaction agreement imposes significant penalties on Theravance Biopharma for accepting competing bids, which could undermine potential shareholder benefits and reflects risks in the company's strategic decision-making process.
- Internal Conflicts of Interest: Insiders at Theravance Biopharma will receive substantial benefits as part of change of control arrangements, raising concerns about governance and conflicts of interest, which may affect investor confidence in the company's future prospects.
See More
Theravance Biopharma Acquired by Zymeworks for $17.00 per Share
- Deal Overview: Zymeworks is acquiring Theravance Biopharma for $17.00 per share in cash, totaling an equity value of $929 million, which represents a 22% premium over the stock's closing price on March 3, 2026, indicating recognition of Theravance's future potential.
- Future Earnings Rights: Theravance shareholders will receive a contingent value right entitling them to 80% of net proceeds related to ampreloxetine over the next ten years, providing additional revenue opportunities for shareholders while enhancing Zymeworks' strategic value.
- Clinical Trial Impact: The topline results of Theravance's CYPRESS phase 3 study, announced on March 3, did not meet its primary endpoint, leading to the decision to wrap up the ampreloxetine program, which may affect the company's future R&D direction and market performance.
- Market Reaction: Following the acquisition announcement, Theravance's stock was down over 2.5% in premarket trading, reflecting cautious market sentiment towards the deal and indicating investor uncertainty regarding the company's future prospects.
See More
Zymeworks Acquires Theravance Biopharma for $929M
- Acquisition Overview: Zymeworks announced its acquisition of Theravance Biopharma in an all-cash deal valued at approximately $929 million, paying $17 per share, aimed at expanding its commercial portfolio with the COPD treatment YUPELRI.
- Financial Impact Analysis: YUPELRI currently generates about $60 million in annual cash flow, and the acquisition includes additional royalty interests, milestone payments, and approximately $2.5 billion in Irish tax attributes, which are expected to significantly enhance Zymeworks' financial position.
- Financing Structure: The deal will be financed primarily through a $350 million non-recourse note from OMERS Life Sciences, Theravance's expected $360 million net cash balance at closing, and $219 million of Zymeworks' cash, showcasing a diverse financing strategy.
- Approval and Expectations: The boards of both companies have unanimously approved the transaction, which is expected to close in the second half of 2026; however, TBPH stock dropped 3% in pre-market trading on Monday, indicating some market skepticism despite the deal's long-term strategic significance.
See More
Theravance Biopharma Acquired by Zymeworks for $17 per Share
- Acquisition Agreement: Theravance Biopharma has entered into a definitive agreement with Zymeworks to be acquired for $17 per share in cash, representing an equity value of approximately $929 million, reflecting market recognition of Theravance's assets.
- Shareholder Benefit Assurance: In addition to cash, Theravance shareholders will receive a contingent value right entitling them to 80% of net proceeds from any future licensing or monetization of ampreloxetine over the next ten years, ensuring their interests in potential future gains.
- Strategic Review Outcome: This transaction is the result of a comprehensive evaluation by Theravance's Strategic Review Committee aimed at maximizing shareholder value, which previously included monetizing the TRELEGY® royalty for $225 million.
- Future Outlook: The transaction is expected to close in the second half of 2026, subject to shareholder and regulatory approvals, providing immediate cash flow to Theravance shareholders while preserving opportunities for future potential earnings.
See More
